Company Focus
AstraZeneca
Latest AstraZeneca News
Pharmaceutical
UK pharma major AstraZeneca today announced a new strategic drug discovery collaboration and licensing agreement with machine learning-enabled drug discovery and development company insitro. 15 October 2026
Related News
Insights
Company Spotlight
A UK life science investor, listed in London and managed by a team the Wellcome Trust founded in 2012, that builds and funds biotech companies from British science and is now focused on returning at least £250 million ($336.8 million) to shareholders from a portfolio of 15 companies.
Latest News & Features of interest to AstraZeneca
Biotechnology
Key analyses from the positive Phase III OBERON and TITANIA trials and results from the PROSPERO long-term extension trial reinforce tozorakimab’s broad and durable benefits in patients with chronic obstructive pulmonary disease (COPD), says UK pharma major AstraZeneca. 12 October 2026
Pharmaceutical
Uptake of new cancer medicines still differs more than three-fold between European countries, though the gap has narrowed since 2018 and the traditional East-West divide is blurring, according to the Swedish Institute for Health Economics’ (IHE) Comparator Report on Cancer in Europe 2025. 12 October 2026
Biotechnology
Antibody-drug conjugates (ADCs) bring together two familiar approaches to cancer treatment: an antibody that recognizes a target on a cell and a powerful drug that kills it. Connecting them offers a way to deliver chemotherapy more selectively, although it does not prevent the medicine from damaging healthy tissue. 12 October 2026
Pharmaceutical
US biotech company Revolution Medicines faces fresh questions about how its pancreatic cancer treatment Rasonque (daraxonrasib) performs across different KRAS mutations, following publication of regulatory review documents. 12 October 2026
Pharmaceutical
Belgian pharma trade group pharma.be welcomes the new Belgian Cancer Plan 2026-2036. The innovative biopharmaceutical sector has been advocating for a new cancer plan for years and is pleased that a framework is now in place to further strengthen the fight against cancer in Belgium. 12 October 2026
Pharmaceutical
September 2026 brought a series of important advances in rare disease treatment, with several therapies receiving their first regulatory approvals. 12 October 2026
Biotechnology
Research findings last week included US vaccines maker Vaxcyte releasing highly impressive Phase III data for its VAX-31, for pneumococcal disease and pneumonia, while US biotech Caribou Biosciences said it will stop development of its CAR-T program, blaming a lack of financing. Dutch drug developer argenx also dropped development of its Vyvgart for the treatment of Sjögren's disease. Also of note, last Thursday Viatris announced plans to acquire fellow USA based Pacira Biosciences for $1.65 billion, 10 October 2026
Pharmaceutical
US biopharma company Mineralys Therapeutics today announced the presentation of a new analysis from its pivotal Phase III Launch-HTN trial, showing that at Week 12, 46% of lorundrostat-treated participants achieved the AHA/ACC Guideline recommended office systolic blood pressure (SBP) target of <130 mmHg. 9 October 2026
Biotechnology
Iambic Therapeutics, the San Diego-based AI drug discovery company, has set terms for a Nasdaq initial public offering of 9,375,000 shares priced at $15 to $17 each, under the proposed ticker IAM, according to an amended S-1 filed with the SEC Thursday. 9 October 2026
Biotechnology
Privately-held Endeavor BioMedicines said its Phase IIb WHISTLE-PF trial of taladegib (ENV-101) met its primary endpoint in idiopathic pulmonary fibrosis (IPF), with a statistically significant improvement in lung function against placebo. 9 October 2026
Latest In Brief for AstraZeneca
Pharmaceutical
Spanish drugmaker PharmaMar has announced that health authorities in Canada, Qatar and South Korea have approved Zepzelca (lurbinectedin) in combination with atezolizumab (Roche’s Tecentriq) for the maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. 25 August 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze